Intravesical Injection of Botox for Treating Therapy Refractory Overactive Bladder in Females

University of Zurich (UZH) logo

University of Zurich (UZH)

Status

Completed

Conditions

Overactive Bladder Syndrome

Study type

Observational

Funder types

Other

Identifiers

NCT01042119
FHKUSZ15-2009

Details and patient eligibility

About

The neurotoxin Botox (botulinum neurotoxin type A) is shown to be effective in the treatment of therapy refractory overactive bladder syndrome. Our data suggests a longer during efficacy than known from the use in striated muscle. The aim of our study is to analyze short- and longterm efficacy after Botox treatment and to evaluate risk factors for non-responders and side effects such as urinary retention.

Enrollment

200 estimated patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

intravesical treatment with Botox at our clinic

Trial design

200 participants in 1 patient group

Botox
Description:
patients who received intravesical injections of botulinum neurotoxin type A

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems